Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22884
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWalterfang, Mark-
dc.contributor.authorDi Biase, Maria A-
dc.contributor.authorCropley, Vanessa L-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorO'Keefe, Graeme J-
dc.contributor.authorVelakoulis, Dennis-
dc.contributor.authorPathmaraj, Kunthi-
dc.contributor.authorAckermann, Uwe-
dc.contributor.authorPantelis, Christos-
dc.date2020-
dc.date.accessioned2020-03-31T03:15:24Z-
dc.date.available2020-03-31T03:15:24Z-
dc.date.issued2020-03-24-
dc.identifier.citationNeurology 2020; online first: 24 Marchen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22884-
dc.description.abstractTo test the hypothesis that neuroinflammation is a key process in adult Niemann-Pick type C (NPC) disease, we undertook PET scanning utilizing a ligand binding activated microglia on 9 patients and 9 age- and sex-matched controls. We scanned all participants with the PET radioligand 11C-(R)-PK-11195 and undertook structural MRI to measure gray matter volume and white matter fractional anisotropy (FA). We found increased binding of 11C-(R)-PK-11195 in total white matter compared to controls (p < 0.01), but not in gray matter regions, and this did not correlate with illness severity or duration. Gray matter was reduced in the thalamus (p < 0.0001) in patients, who also showed widespread reductions in FA across the brain compared to controls (p < 0.001). A significant correlation between 11C-(R)-PK11195 binding and FA was shown (p = 0.002), driven by the NPC patient group. Our findings suggest that neuroinflammation-particularly in white matter-may underpin some structural and degenerative changes in patients with NPC.en
dc.language.isoeng-
dc.titleImaging of neuroinflammation in adult Niemann-Pick type C disease: A cross-sectional study.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeurologyen
dc.identifier.affiliationFrom the Neuropsychiatry Unit (M.W., D.V.), Royal Melbourne Hospital; Melbourne Neuropsychiatry Centre (M.W., M.A.D., V.L.C., D.V., C.P.), The University of Melbourne & North Western Mental Health; The Florey Institute of Neuroscience and Mental Health (M.W., C.P.), Department of Psychiatry (M.W., M.A.D., V.L.C., D.V., C.P.), and Centre for Neural Engineering, Department of Electrical and Electronic Engineering (C.P.), The University of Melbourne; Department of Molecular Imaging and Therapy (A.M.S., G.O., K.P., U.A.), Austin Health and The University of Melbourne, Heidelberg; Olivia Newton John Cancer Centre and La Trobe University (A.M.S., G.O., U.A.), Melbourne; and Cooperative Centre for Mental Health Research (C.P.), Carlton, Australiaen
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1212/WNL.0000000000009287en
dc.type.contentTexten
dc.identifier.orcid0000-0002-1389-3691en
dc.identifier.orcid0000-0002-7100-651Xen
dc.identifier.orcid0000-0003-0029-1525en
dc.identifier.orcid0000-0002-6656-295Xen
dc.identifier.orcid0000-0002-8842-8479en
dc.identifier.orcid0000-0002-9565-0238en
dc.identifier.pubmedid32209649-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Jan 23, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.